

SEQUENCE LISTING

<110> NAGATA, Shigekazu TANAKA, Masato

<120> Novel Fas Ligand Derivative

<130> 1110-0266P

<140> 09/508,849 <141> 2001-03-17

<150> PCT/JP98/04187

<151> 1998-09-17

<150> JP 9-252541 <151> 1997-09-17

<160> 17

<170> PatentIn version 3.2

<210> 1

<211> 258

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:amino acids at 111-133 from N terminal are deleted from natural human Fas ligand

<400> 1

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp 1 5 10 15

Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys 20 25 30

Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro 35 40 45

Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro 50 55 60

Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly 65 70 75 80

Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly
85 90 95

Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Pro Ser 100 105 110

Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His Leu Thr Gly
115 120 125

TECH CENTER 1800/2800

Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp Thr Tyr Gly
130

135

140

Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly Leu Val Ile
145

150

155

160

Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr Phe Arg Gly 165 170 175

Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr Met Arg Asn 180 185 190

Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys Met Met Ser 195 200 205

Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu Gly Ala 210 215 220

Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn Val Ser Glu 225 230 235 240

Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly Leu Tyr 245 250 255

Lys Leu

<210> 2

<211> 277

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:amino acids at 128-131 from N terminal are deleted from natural human Fas ligang

<400> 2

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp 1 5 10 15

Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys 20 25 30

Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro 35 40 45

Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Leu Pro 50 55 60

Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly 65 70 75 80

Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly 85 90 95

Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala 100 110 Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Gly 120 His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His 135 Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly 170 Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr 185 Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr 195 200 Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys 215 220 Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr 230 235 240 225 Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn

Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe 260 265 270

Gly Leu Tyr Lys Leu

<210> 3

<211> 281

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:point mutation
 of a substitution of Lys 129 for Ala from N
 terminal is present in natural human Fas ligand
 <D6>

<400> 3

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp 1 5 10 15

Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys
20 25 30

Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro 35 40 45

Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Leu Pro
50 55 60

Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly 65 70 75 80

Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly 85 90 95

Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala 100 105 110

Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu 115 120 125

Ala Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg 130 135 140

Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu 145 150 155 160

Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr 165 170 175

Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr 180 185 190

Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser 195 200 205

His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met 210 215 220

Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala 225 230 235 240

Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His
245 250 255

Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser 260 265 270

Gln Thr Phe Phe Gly Leu Tyr Lys Leu 275 280

<210> 4

<211> 774

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA coding for amino acids SEQ ID No.1

<400> 4

```
atgcagcagc cetteaatta eccatateee cagatetaet gggtggaeag eagtgeeage 60
tctccctggg cccctccagg cacagttctt ccctgtccaa cctctgtgcc cagaaggcct 120
qqtcaaagga ggccaccacc accaccgcca ccgccaccac taccacctcc gccgccgccg 180
ccaccactgc ctccactacc gctgccaccc ctgaagaaga gagggaacca cagcacaggc 240
ctqtqtctcc ttqtqatqtt tttcatqqtt ctqqttqcct tqqtagqatt gggcctgggg 300
atqtttcaqc tcttccacct acagaaggag cccaqtccac cccctgaaaa aaaggagctg 360
aggaaagtgg cccatttaac aggcaagtcc aactcaaggt ccatgcctct ggaatgggaa 420
gacacctatg gaattgtcct gctttctgga gtgaagtata agaagggtgg ccttgtgatc 480
aatgaaactg ggctgtactt tgtatattcc aaagtatact tccggggtca atcttgcaac 540
aacctgcccc tgagccacaa ggtctacatg aggaactcta agtatcccca ggatctggtg 600
atgatggagg ggaagatgat gagctactgc actactgggc agatgtgggc ccgcagcagc 660
tacctggggg cagtgttcaa tcttaccagt gctgatcatt tatatgtcaa cgtatctgag 720
ctctctctgg tcaattttga ggaatctcag acgtttttcg gcttatataa gctc
<210> 5
<211> 831
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: DNA coding for
      amino acids SEQ ID No.2
<400> 5
atgcagcagc cottoaatta cocatatooc cagatotact gggtggacag cagtgccage 60
tetecetggg ecceteeagg caeagttett ecctgteeaa ectetgtgee eagaaggeet 120
ggtcaaagga ggccaccacc accaccgcca ccgccaccac taccacctcc gccgccgccg 180
ccaccactgc ctccactacc gctgccaccc ctgaagaaga gagggaacca cagcacaggc 240
ctgtgtctcc ttgtgatgtt tttcatggtt ctggttgcct tggtaggatt gggcctgggg 300
atgtttcagc tcttccacct acagaaggag ctggcagaac tccgagagtc taccagccag 360
atgcacacag catcatcttt gggccacccc agtccacccc ctgaaaaaaa ggagctgagg 420
aaagtggccc atttaacagg caagtccaac tcaaggtcca tgcctctgga atgggaagac 480
acctatggaa ttgtcctgct ttctggagtg aagtataaga agggtggcct tgtgatcaat 540
qaaactqqqc tqtactttqt atattccaaa qtatacttcc ggqqtcaatc ttgcaacaac 600
ctgcccctga gccacaaggt ctacatgagg aactctaagt atccccagga tctggtgatg 660
atggagggga agatgatgag ctactgcact actgggcaga tgtgggcccg cagcagctac 720
ctgggggcag tgttcaatct taccagtgct gatcatttat atgtcaacgt atctgagctc 780
tctctqqtca attttqaqqa atctcaqacq tttttcqqct tatataaqct c
<210> 6
<211> 843
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: DNA coding for
      amino acids SEQ ID No.3
<400> 6
atgeageage cetteaatta cecatateee cagatetaet gggtggacag cagtgecage 60
tetecetggg ecceteeagg caeagttett ecctgteeaa ectetgtgee eagaaggeet 120
ggtcaaagga ggccaccacc accaccgcca ccgccaccac taccacctcc gccgccgccg 180
ccaccactgc ctccactacc gctgccaccc ctgaagaaga gagggaacca cagcacaggc 240
ctgtgtctcc ttgtgatgtt tttcatggtt ctggttgcct tggtaggatt gggcctgggg 300
atgtttcagc tcttccacct acagaaggag ctggcagaac tccgagagtc taccagccag 360
```

```
atgcacacag catcatcttt ggaggcacaa ataggccacc ccagtccacc ccctgaaaaa 420
aaggagetga ggaaagtgge ceatttaaca ggeaagteea aeteaaggte catgeetetg 480
gaatgggaag acacctatgg aattgtcctg ctttctggag tgaagtataa gaagggtggc 540
cttgtgatca atgaaactgg gctgtacttt gtatattcca aagtatactt ccggggtcaa 600
tcttgcaaca acctgcccct gagccacaag gtctacatga ggaactctaa gtatccccag 660
gatctggtga tgatggaggg gaagatgatg agctactgca ctactgggca gatgtgggcc 720
cgcagcagct acctgggggc agtgttcaat cttaccagtg ctgatcattt atatgtcaac 780
gtatctgagc tctctctggt caattttgag gaatctcaga cgtttttcgg cttatataag 840
ctc
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:a sense primer
      BOS 6
<400> 7
                                                                   20
cctcagacag tggttcaaag
<210> 8
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:an antisense
      deletion primer DA4
<400> 8
ttttcagggg gtggactggg ctccttctgt aggtggaag
                                                                   39
<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: HFLP3
<400> 9
gctctagaac attctcggtg cctgtaac
                                                                   28
<210> 10
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:DA5
<400> 10
```

```
30
tggactgggg tggcccaaag atgatgctgt
<210> 11
<211> 33
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence:DA6
<400> 11
                                                                    33
ggggtggcct atttgtgcct ccaaagatga tgc
<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:sequence of
      human FasL from amino acids 130 to137
<400> 12
Gln Ile Gly His Pro Ser Pro Pro
<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: the amino acid
      sequence around the cleavage site of FasL
<400> 13
Glu Lys Gln Ile
 1
<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: the cleavage
      site of THN-alpha
<400> 14
Leu Ala Gln Ala Val Arg Ser Ser
  1
                  5
```

```
<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: the cleavage
      site of CD40
<400> 15
Asn Ser Phe Glu Met Gln Lys Gly
<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: the cleavage
      site of FasL
<400> 16
Ser Leu Glu Lys Gln Ile Gly His
<210> 17
<211> 281
<212> PRT
<213> Homo sapiens
<400>
       17
Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp
                5
Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys
Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro
                            40
Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Leu Pro
Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly
Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly
Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala
            100
                                105
                                                    110
Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu
```

115 120 125

Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg 130 135 140

Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu 145 150 155 160

Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr 165 170 175

Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr 180 185 190

Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser 195 200 205

His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met 210 215 220

Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala 225 230 235 240

Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His 245 250 255

Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser 260 265 270

Gln Thr Phe Phe Gly Leu Tyr Lys Leu 275 280